NCT02603445View on ClinicalTrials.gov

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 16, 2015

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions
Follicular Lymphoma, Mantle Cell Lymphoma
Interventions
DRUG

BCL201

DRUG

Idelalisib

Trial Locations (7)

5020

Novartis Investigative Site, Salzburg

10017

Novartis Investigative Site, New York

31059

Novartis Investigative Site, Toulouse

55131

Novartis Investigative Site, Mainz

69495

Novartis Investigative Site, Pierre-Bénite

77030

Novartis Investigative Site, Houston

79106

Novartis Investigative Site, Freiburg im Breisgau

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY